Search Names & Symbols

With personal love and passion we work alone and analyze our favorite shares. May not be many, but they are worth it.

The best online stock broker. Open an account today and start earning up to $1000 of IBKR Stock !

Thursday, November 10, 2022

The dividend history of OPAP since 2001

The dividend king is here

Opap is the dividend king by StockBlog on TradingView.com




High Dividend Stocks (Greece)

Tuesday, September 27, 2022

3M Company (MMM) REVENUE

 3M Company (MMM)  REVENUE 


Monday, August 29, 2022

Bayer initiates landmark Phase III study program to investigate oral FXIa inhibitor asundexian

 

The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke events in patients with atrial fibrillation as well as patients with a non-cardioembolic ischemic stroke or high-risk transient ischemic attack involving up to 30,000 patients / Bayer drives the development of its FXIa inhibitor, with the goal of offering a potential new class of antithrombotics for improved outcomes for patients using selective coagulation modulation
 

Tuesday, August 9, 2022

Thursday, July 21, 2022

Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2022 Financial Results on August 4, 2022

 sAN FRANCISCO, July 21, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the second quarter ended June 30, 2022, on Thursday, August 4, 2022.

The corporate update and financial results will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at www.vir.bio.

About Vir Biotechnology
Vir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B and D viruses, influenza A and human immunodeficiency virus. Vir routinely posts information that may be important to investors on its website.

 


Contacts: Investors Heather Rowe Armstrong VP, Investor Relations harmstrong@vir.bio +1-415-915-4228 Media Carly Scaduto Senior Director, Media Relations cscaduto@vir.bio +1 314-368-5189

Saturday, July 16, 2022

Vroom Announces Pricing of UACC Auto Loan Securitization

 Vroom Announces Pricing of UACC Auto Loan Securitization


Jul 15, 2022

NEW YORK--(BUSINESS WIRE)--Jul. 15, 2022-- Vroom (NASDAQ: VRM), an innovative ecommerce platform that offers a better way to buy and sell used vehicles, today announced that United Auto Credit Corporation (UACC), an indirect wholly-owned subsidiary of the company, priced an auto loan securitization of $255.080 million in aggregate principal amount of automobile receivable backed notes (the “Notes”) on July 14, 2022.

The Q3 2022 securitization is a private offering under Rule 144A in which UACC offered approximately $242.325 million of the Notes. The transaction represents UACC's 14th securitization overall and second since its acquisition by Vroom on February 1, 2022. The transaction features five classes of sequential-pay securities with expected ratings of AAA/AAA through BB/BB by S&P Global Ratings and DBRS Morningstar, respectively.

UACC expects to sell approximately $285.000 million in principal balance of auto loans to a special purpose trust and receive proceeds from the issuance and sale of the rated Notes. UACC will retain a 5% vertical risk retention interest in each class of Notes in order to satisfy the U.S. credit risk retention regulations.

Thursday, July 14, 2022

Thessaloniki Port Authority Societe Anonyme NET INCOME €

 Thessaloniki Port Authority Societe Anonyme  NET INCOME € 


Corsair Gaming, Inc. (CRSR-NASDAQ) TOTAL ASSETS VS TOTAL LIABILITIES

 Corsair Gaming, Inc. (CRSR-NASDAQ) TOTAL ASSETS VS TOTAL LIABILITIES


Bayer to sell men’s health product Nebido™ to Grünenthal

 

Bayer to sell men’s health product Nebido™ to Grünenthal


Supports ongoing transformation of Bayer’s Pharma business to focus on key areas of future medical innovation / Transaction value of up to 500 million Euro / Closing expected by end of 2022
 
Berlin, July 14, 2022 – Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer’s men’s health product Nebido™ (testosterone undecanoate), for a purchase price totaling up to 500 million Euro.

Twitter to Announce Second Quarter 2022 Results

 Twitter to Announce Second Quarter 2022 Results


GAS LOG - SUSTAINABLE REPORT

READ HERE

Tuesday, July 5, 2022

QUEST HOLDINGS - RATIOS

 

RATIOSQUEST
P/E3,5
P/S0,47
P/BV1,7
ROE21%
ROI39%
DIVIDEND YIELD13%

Friday, July 1, 2022

CLOU - ETF FOR THE FUTURE


CLOU - ETF FOR THE FUTURE by StockBlog on TradingView.com

After the big drop in tech stocks in recent months, this etf , that follows cloud companies, is a very good investment option for those who look to the future...

Quest Holdings ( ATHEX ) NET INCOME

 Quest Holdings ( ATHEX ) NET INCOME


Thursday, June 30, 2022

ISHARES CHINA LARGE-CAP ETF - STAY LONG

 


STAY LONG by StockBlog on TradingView.com

Exxon Mobil NET INCOME $

 Exxon Mobil   NET INCOME $ 


Quest Holdings ( ATHEX ) REVENUE

 Quest Holdings ( ATHEX ) REVENUE 


Sunday, June 26, 2022

Vir Biotechnology Announces New Clinical Data From its Broad Hepatitis B Program






– Results from ongoing trials of VIR-2218 and VIR-3434 presented at the International
Liver Congress™ (ILC) 2022 demonstrate durable reductions in hepatitis B surface antigen with no safety signals –

– Company expects to dose first patient in Part B of the Phase 2 MARCH trial by the end of June –

SAN FRANCISCO, June 25, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new data from its robust hepatitis B virus (HBV) clinical trial program, including results from an ongoing Phase 2 clinical trial of VIR-2218, results from an ongoing Phase 1 clinical trial of VIR-3434 and preclinical data evaluating both investigational compounds as monotherapy and in combination. Data were presented in one oral and two poster presentations at the International Liver Congress™ (ILC) 2022, the Annual Meeting of the European Association for the Study of the Liver (EASL).

Winner of the week

 Vroom (VRM-NASDAQ)  +21,67 %



ΑΤ & Τ (Τ- NYSE) FAIR PRICE vs PRICE

 ΑΤ & Τ (Τ- NYSE)  FAIR PRICE vs PRICE


Saturday, June 18, 2022

WINNER OF THE WEEK

 Unipro (UPRO)

+11,38%
Moscow

INTERACTIVE BROKERS: 

The best online stock broker. Open an account today and start earning up to $1000 of IBKR Stock !




DISCLAIMER: The financial and technical analycies presented on this website have not been performed by an Investment Services Company, nor have they been compiled by a certified analyst . It is simply a display and presentation of public data of Greek and foreign shares with informative and entertaining character.

AT&T Inc (T - NYSE) DIVIDENDS

 AT&T Inc (T - NYSE) DIVIDENDS



AT&T Inc (T - NYSE) - REVENUE

 



Wednesday, June 15, 2022

BITCOIN DEATH CROSS

BITCOIN DEATH CROSS by StockBlog on TradingView.com

DISCLAIMER:

The financial and technical analycies presented on this website have not been performed by an Investment Services Company, nor have they been compiled by a certified analyst . It is simply a display and presentation of public data of Greek and foreign shares with informative and entertaining character.

My opinion on the shares of our site

Τhe situation of the stock market